The frustration in European capital markets is boiling over. In a presentation featuring a slide of a “blue turkey” carrying an EU flag, Hughes Beuzelin, CEO of French asset manager BDL Capital Management (€3.5B AUM), delivered a blistering critique of Brussels’ regulatory agenda. His message? Europe is regulating its own financial sector into irrelevance. 📉...
The man behind Keytruda is back to ring the bell. Eikon Therapeutics, led by former Merck research chief Roger Perlmutter, has set terms for its Nasdaq debut. The company is targeting a valuation of up to $908.2 million (“EIKN”), seeking to raise ~$318 million as the biotech IPO window opens wide in early 2026. 🔬...
The Brazilian IPO drought in New York is officially over. PicPay, the digital banking giant backed by the billionaire Batista family, is expected to price its IPO at the top of its $16 – $19 range on Wednesday. After shelving plans in 2021 due to market headwinds, the company’s return marks a critical turning point...
Snap is admitting that building hardware is too expensive to do alone on an ad-revenue balance sheet. Snap Inc. (SNAP) announced Wednesday it is creating an independent subsidiary, “Specs,” for its AR smart glasses. The strategic move allows the unit to attract external minority investment to fund the massive R&D costs required to challenge Meta...
The “Big Two” proxy advisors are losing their grip on Wall Street’s biggest voting blocks. Wells Fargo’s Wealth & Investment Management unit ($2.5 trillion AUM) announced Wednesday it is launching an internal proxy voting service, effectively severing ties with ISS (Institutional Shareholder Services). The move aligns the bank with a growing trend of major asset...
The man behind Keytruda is back to ring the bell. Eikon Therapeutics, led by former Merck research chief Roger Perlmutter, has set terms for its Nasdaq debut (“EIKN”). The company is targeting a valuation of $908 million, seeking to raise up to $317.7 million as the biotech IPO window creaks open in early 2026. 🔬...